Nasal Polyposis Treatment Market Benefits from Severe CRSwNP Biologic Expansion and Steroid-Sparing Treatment Demand

The Global Nasal Polyposis Treatment Market was valued at USD 4.94 billion in 2025 and is projected to reach USD 7.79 billion by 2032, growing at a CAGR of 6.72%, according to Strategic Market Research.

 

The Nasal Polyposis Treatment Market is commercially established across intranasal corticosteroids, short-course oral corticosteroids, sinus surgery, and biologics used for severe chronic rhinosinusitis with nasal polyps, or CRSwNP.

 

Revenue growth is concentrated in patients who remain uncontrolled after steroid therapy or surgery, develop recurrent polyps, carry asthma or type 2 inflammation, and meet payer-defined severity thresholds. Broad sinusitis prevalence supports the baseline treatment and procedure pool, but biologic adoption depends on documented severe uncontrolled CRSwNP rather than general nasal or sinus symptom burden.

 

Mayo Clinic and Cleveland Clinic both place steroid nasal sprays, oral steroids, biologics, and surgery within the treatment pathway. Polyps can recur after surgery, so patients often remain on medical therapy even after procedural intervention. That treatment pattern keeps low-cost therapies relevant while shifting higher-value demand toward biologics in recurrent and uncontrolled disease.

 

Diagnosed CRSwNP, Not Broad Sinusitis, Defines the Treatable Pool

CRSwNP has a meaningful prevalence base, but the addressable biologic population is much smaller than broad sinusitis statistics imply. A 2025 global systematic review estimated pooled CRSwNP prevalence at 0.65% of the general population. Another systematic review reported prevalence across studies at about 1%–2.6%, with higher rates among men. Diagnosis, endoscopic confirmation, symptom severity, prior therapy failure, and reimbursement rules narrow that pool before premium drugs enter the pathway.  

U.S. sinusitis statistics provide useful healthcare-utilization context but not a direct nasal-polyposis drug opportunity. CDC reported 28.9 million U.S. adults, or 11.6%, with diagnosed sinusitis in 2018, along with 2.7 million physician-office visits where chronic sinusitis was the primary diagnosis. Those numbers support demand for physician visits, sprays, steroids, imaging, antibiotics, and ENT evaluation; they do not represent the CRSwNP biologic population.

European claims data give a cleaner treated-population benchmark. A German claims analysis estimated diagnosed CRSwNP prevalence at about 5,500 per million adults, or 0.55%, while severe inadequately controlled CRSwNP affected about 200 per million people. Standard therapies cover the diagnosed pool, while biologic revenue is concentrated in the severe uncontrolled subgroup where steroid use, surgery history, recurrence, and quality-of-life burden are documented.

 

Steroid Use Holds Volume and Identifies Escalation Candidates

Intranasal corticosteroids remain the largest recurring treatment base because they are used before surgery, after surgery, and alongside biologics. In the German claims study, 80.55% of newly diagnosed CRSwNP patients received intranasal corticosteroids within 12 months. Over about two years, 83.0% used intranasal corticosteroids. Topical steroid prescribing therefore remains durable even as biologic competition expands.

Oral corticosteroids define the patients most likely to move into higher-value treatment. In the same German study, 24.27% of newly diagnosed patients received at least one systemic corticosteroid within 12 months, increasing to 31.32% over about two years. Among severe inadequately controlled patients, 72.86% received systemic corticosteroids during follow-up. Repeated oral-steroid exposure gives clinicians and payers a measurable reason to consider biologic therapy.

Medscape describes oral corticosteroids as an effective short-term option for nasal polyps, but repeat exposure limits their long-term role. Biologic manufacturers therefore compete on steroid reduction as much as symptom improvement, especially in severe patients where repeated systemic therapy creates safety concerns and payer scrutiny.

 

Surgery Remains Central, but Recurrence Keeps Patients in Treatment

Endoscopic sinus surgery remains a major revenue event because many patients do not achieve durable control with medicines alone. The German claims analysis found that 17.33% of newly diagnosed CRSwNP patients underwent functional endoscopic sinus surgery within 12 months, increasing to 19.73% over about two years. Surgery is also built into many biologic access rules, making it both a treatment event and a gateway marker for advanced therapy.

Post-surgery recurrence keeps CRSwNP from behaving like a one-time procedural category. A prospective cohort found nasal-polyp recurrence in approximately 35% of patients at six months, 38% at 12 months, and 40% at 18 months after endoscopic sinus surgery despite continued medical management. Recurrence drives repeat ENT visits, ongoing steroid use, revision-risk monitoring, and biologic consideration in patients with persistent inflammatory disease.

Long-term surgical data add another reason for sustained medical demand. A U.S. population-database study of 29,934 endoscopic sinus surgery patients followed for a mean of 9.7 years reported an overall revision-surgery rate of 15.9%. CRSwNP patients had a higher revision burden than patients with chronic rhinosinusitis without polyps. Chronic recurrence keeps drug therapy commercially relevant even when surgery remains part of the pathway.

 

Approved Biologics Are Competing for Severe, Documented Disease

The approved treatment landscape is split between low-cost chronic care and premium biologics. Intranasal corticosteroids and oral corticosteroids support broad prescribing. Sinus surgery captures refractory disease and procedural demand. Biologics serve severe uncontrolled CRSwNP, especially when prior steroids, prior surgery, asthma overlap, type 2 inflammation, or high symptom scores justify advanced treatment.

Dupilumab remains the leading biologic reference point. In pooled SINUS analyses, dupilumab reduced the need for sinonasal surgery and systemic corticosteroid use versus placebo in severe CRSwNP. NICE’s 2026 review placed dupilumab in a restricted severe population requiring inadequate control after systemic corticosteroids or sinus surgery, at least one previous sinus operation, and a SNOT-22 score of at least 50. Dupilumab has strong evidence and access recognition, but reimbursement remains tied to documented severity.  

Omalizumab remains important where anti-IgE positioning fits the patient profile. POLYP 1 and POLYP 2 enrolled 138 and 127 patients, respectively, and showed significant improvement in nasal-polyp score, nasal congestion, SNOT-22, and smell-related outcomes versus placebo in severe CRSwNP with inadequate response to intranasal corticosteroids. Biosimilar entry is now changing the access and pricing conversation around omalizumab, especially in payer-sensitive settings.

Mepolizumab holds a role in recurrent, refractory severe CRSwNP, particularly in eosinophilic and asthma-overlap patients. The SYNAPSE trial included 407 patients and showed improvement in nasal-polyp size and nasal obstruction versus placebo without new safety signals. Long-acting IL-5 competition from depemokimab will pressure differentiation in markets where Exdensur is approved for CRSwNP.

 

Tezspire and Exdensur Shift Competition Toward Mechanism and Dosing

Tezspire changed U.S. biologic competition in October 2025 when the FDA approved tezepelumab-ekko as add-on maintenance treatment for inadequately controlled CRSwNP in patients aged 12 years and older. Tezepelumab added TSLP inhibition to a market previously built around IL-4/IL-13, IL-5, and IgE pathways.

WAYPOINT gave Tezspire a strong launch argument because the data linked clinical response to reduced escalation. The Phase III trial showed significant reductions in nasal-polyp size and nasal congestion, while AstraZeneca reported a 98% reduction in surgery need and an 88% reduction in systemic corticosteroid treatment versus placebo. Surgery and steroid reduction carry stronger payer relevance than symptom improvement alone.

Exdensur changed the dosing conversation outside the United States. The European Commission approved GSK’s depemokimab in February 2026 for adults with severe CRSwNP inadequately controlled by systemic corticosteroids and/or surgery. GSK positioned Exdensur as an ultra-long-acting biologic with twice-yearly dosing, supported by SWIFT and ANCHOR Phase III data. In a chronic specialty market where several biologics require every-two-week or every-four-week administration, dosing frequency can influence adherence, clinic workload, and payer preference.

GSK expanded Exdensur into China in April 2026 and Canada in June 2026. The U.S. remains different because Reuters reported FDA approval for severe eosinophilic asthma but not the CRSwNP indication. As a result, Exdensur competes in several non-U.S. CRSwNP markets, while U.S. biologic competition remains centered on Dupixent, Xolair/Omlyclo, Nucala, and Tezspire.

 

Pipeline Activity Is Focused on Better Fit, Not More Treatment Labels

Pipeline development is moving toward longer dosing intervals, upstream inflammatory targets, asthma-overlap positioning, and stronger steroid- or surgery-sparing evidence. Another biologic label will not be enough unless the product offers clearer patient selection, lower treatment burden, or a measurable reduction in escalation events.

Verekitug from Upstream Bio is one of the more relevant pipeline signals. The Phase 2 VIBRANT trial evaluated verekitug every 12 weeks in 81 adults with severe inadequately controlled CRSwNP despite standard intranasal steroids. Reported data showed reductions in nasal-polyp size, nasal symptoms, and the need for endoscopic sinus surgery or systemic corticosteroids. The dosing interval and escalation-event data give verekitug a clearer commercial argument than symptom improvement alone.

GLP-1 receptor agonist research has opened an adjacent but still early signal. A 2026 retrospective study in 1,391 matched patient pairs with obesity and CRSwNP after functional endoscopic sinus surgery found GLP-1 receptor agonist use was associated with a 36% lower revision-surgery rate at one year, 40% lower revision rate at five years, and 28% fewer first-time biologic prescriptions. Observational evidence does not establish GLP-1 drugs as nasal-polyp treatments, but obesity-linked inflammatory risk and postoperative recurrence could become useful research angles for future patient stratification.

Omalizumab biosimilar activity is changing the access environment. The FDA label for Omlyclo states that omalizumab-igec is indicated as add-on maintenance treatment for CRSwNP in adults aged 18 years and older with inadequate response to nasal corticosteroids. Kashiv BioSciences also announced Health Canada validation and acceptance of the marketing authorization application for ADL-018, a proposed Xolair biosimilar, in June 2026. Anti-IgE therapy is therefore more exposed to payer and price competition than newer patented biologics.  

 

Access Rules Are Narrowing the Premium Segment

Biologic adoption is controlled by severity documentation. NICE’s 2026 recommendation allows dupilumab with intranasal corticosteroids for adults with severe CRSwNP when disease is not controlled well enough by systemic corticosteroids or sinus surgery, the patient has had at least one sinus surgery, and SNOT-22 is at least 50. Patient-reported burden now functions as an access gate, not only as a clinical endpoint.

EPOS/EUFOREA criteria apply a similar filter. Biologics are generally considered after surgery in patients with bilateral polyps who meet multiple criteria, including type 2 inflammation, systemic-steroid need, impaired quality of life, smell loss, and comorbid asthma. The 2023 framework lowered the blood-eosinophil threshold to 150 cells/µL, which may expand eligibility at the margin, but biologics remain focused on severe uncontrolled disease.

Real-world use already follows these constraints. In a U.S. claims study of 74,480 CRSwNP patients, about 12.0% received a biologic. Among included biologic users, 89.8% received dupilumab, 5.3% mepolizumab, and 4.8% omalizumab. Biologic-treated patients had higher asthma prevalence than the overall CRSwNP cohort, 72.4% versus 30.9%, and higher previous nasal-polyp surgery, 15.8% versus 5.8%. High-burden and multimorbid patients are capturing biologic use ahead of routine nasal-polyp cases.

 

Cost Burden Supports Premium Therapy Only in Selected Patients

CRSwNP creates healthcare cost through medication cycles, physician visits, surgery, revision surgery, asthma overlap, and productivity loss. A U.S. MarketScan analysis comparing 10,841 CRSwNP patients with matched controls found annual incremental healthcare costs of USD 11,507 per CRSwNP patient. Annual costs were highest among patients undergoing sinus surgery at USD 26,724, followed by patients with asthma, macrolide users, and oral-corticosteroid users. Premium therapy has the strongest economic case when it reduces steroid exposure and surgery use in high-cost patients.

NICE’s preferred cost-effectiveness estimate for dupilumab in the restricted severe population was £24,846 per quality-adjusted life-year gained, within its accepted range. Cost-effectiveness acceptance in severe CRSwNP does not imply broad biologic coverage. Payers are likely to keep access tied to prior surgery, high symptom burden, systemic-steroid failure, and negotiated commercial terms.

 

North America and Regional Market Behavior

North America remains the strongest commercial region because the United States has multiple approved biologics, high specialty-drug pricing, large respiratory and ENT claims volume, and established allergy, pulmonology, and ENT referral networks. Tezspire’s 2025 approval added a new upstream mechanism, while Omlyclo’s entry created biosimilar pressure in the omalizumab segment. Dupilumab remains the early real-world leader, but U.S. competition is now broader than a single-molecule biologic market.

Europe is the most disciplined reimbursement region. NICE restricts dupilumab to severe post-surgery patients with high SNOT-22 burden, while the European Commission approval of Exdensur introduced a twice-yearly biologic option. European uptake will depend on how payers weigh dosing convenience, steroid reduction, surgery avoidance, and switching from established biologics.

Asia-Pacific is gaining relevance through approval expansion rather than prevalence alone. GSK’s Exdensur approvals in Japan and China place long-acting biologics in major Asian specialty markets. Uptake will depend on reimbursement depth, specialist access, biologic affordability, and local patterns of eosinophilic and non-eosinophilic disease.

 

Market Outlook

Intranasal corticosteroids will continue to anchor high-volume treatment, while oral corticosteroids and sinus surgery remain central to escalation. Biologic growth will come from severe uncontrolled CRSwNP patients with repeated steroid exposure, prior surgery, asthma overlap, type 2 inflammation, high SNOT-22 scores, or recurrence after surgery.

Dupilumab has the strongest early real-world position. Tezspire adds upstream TSLP inhibition with strong steroid- and surgery-reduction messaging. Exdensur offers twice-yearly dosing in approved non-U.S. CRSwNP markets. Omlyclo and ADL-018 introduce biosimilar pressure around omalizumab. Verekitug and other pipeline assets need evidence that longer dosing intervals, durable symptom control, and reduced surgery or steroid need can justify adoption against approved biologics.

Revenue will follow documented severe CRSwNP rather than broad sinusitis prevalence. The strongest indicators are diagnosed CRSwNP prevalence, severe uncontrolled share, systemic corticosteroid frequency, post-surgery recurrence, revision-surgery rates, SNOT-22 thresholds, asthma overlap, biologic discontinuation, biosimilar entry, and regional reimbursement decisions.

 

Nasal Polyposis Treatment Market Report Coverage Table

Report Attribute	Details
Forecast Period	2026 – 2032
Market Size Value in 2025	USD 4.94 Billion
Revenue Forecast in 2032	USD 7.79 Billion
Overall Growth Rate	CAGR of 6.72% (2026 – 2032)
Base Year for Estimation	2025
Historical Data	2019 – 2024
Unit	USD Million, CAGR (2026 – 2032)
Segmentation	By Treatment Type, By Disease Severity, By Biologic Class, By End User, By Geography
By Treatment Type	Intranasal Corticosteroids, Oral Corticosteroids, Biologics, Endoscopic Sinus Surgery, Supportive Therapies
By Disease Severity	Mild to Moderate CRSwNP, Severe Uncontrolled CRSwNP
By Biologic Class	IL-4/IL-13 Inhibitors, Anti-IgE Therapy, IL-5 Inhibitors, TSLP Inhibitors, Other Pipeline Biologics
By End User	Hospitals, ENT Specialty Clinics, Allergy & Pulmonology Clinics, Ambulatory Surgical Centers
By Region	North America, Europe, Asia-Pacific, Latin America, Middle East and Africa
Country Scope	U.S., Canada, UK, Germany, France, Italy, China, Japan, South Korea, India, Brazil, Mexico, Saudi Arabia, UAE, South Africa
Market Drivers	Growing prevalence of severe CRSwNP Rising adoption of biologic therapies Increasing demand for steroid-sparing treatment approaches
Customization Option	Available upon request